| |
| |
|
| Insider
Information: |
Foehr Matthew W |
| Relationship: |
President and CEO, Dir... |
| City: |
Palo Alto |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
3,948,737 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$35,895,547 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
3,948,737 |
|
|
| Total
Value |
$35,895,547 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
13
|
4
|
|
Stock
price went up :
|
8
|
0
|
| Stock
price went down : |
5
|
4
|
| |
|
|
|
Gain/Loss Ratio : |
1.6
|
-4.0
|
| Percentage
Gain/Loss : |
 36.4%
|
 -89.3%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Ligand Pharmaceuticals Inc |
LGND |
Former Executive Officer |
2022-11-01 |
162,187 |
2011-04-18 |
0 |
Premium* |
|
|
Viking Therapeutics, Inc. |
VKTX |
Director |
2022-05-02 |
111,250 |
2015-05-04 |
0 |
Premium* |
|
|
Qualigen Therapeutics Inc |
QLGN |
Director |
2020-04-10 |
138,635 |
2015-06-24 |
0 |
Premium* |
|
|
OmniAb, Inc |
OABI |
President and CEO, Dir... |
2024-05-24 |
3,536,665 |
2022-11-01 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
136 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 2 of 6
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| LGND |
Ligand Pharmaceuticals In... |
EVP and COO |
• – – |
2014-02-14 |
4 |
AS |
$79.54 |
$1,789,650 |
D/D |
(22,500) |
53,457 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2015-06-22 |
4 |
AS |
$95.77 |
$2,222,815 |
D/D |
(23,046) |
68,128 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2015-06-26 |
4 |
AS |
$100.97 |
$1,262,125 |
D/D |
(12,500) |
70,128 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2018-09-04 |
4 |
AS |
$255.01 |
$3,060,082 |
D/D |
(12,000) |
103,300 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2018-10-01 |
4 |
AS |
$273.88 |
$3,286,560 |
D/D |
(12,000) |
105,388 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2020-02-14 |
4 |
AS |
$95.84 |
$692,467 |
D/D |
(7,225) |
156,229 |
0 |
% |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2020-02-27 |
4 |
AS |
$110.00 |
$794,750 |
D/D |
(7,225) |
153,743 |
0 |
% |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2020-08-21 |
4 |
AS |
$112.88 |
$815,541 |
D/D |
(7,225) |
155,413 |
0 |
% |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2020-08-24 |
4 |
AS |
$110.89 |
$8,649 |
D/D |
(78) |
155,413 |
0 |
% |
|
| LGND |
Ligand Pharmaceuticals In... |
EVP and COO |
• – – |
2012-12-05 |
4 |
B |
$17.99 |
$6,656 |
D/D |
370 |
37,870 |
2.74 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
EVP and COO |
• – – |
2013-06-28 |
4 |
B |
$17.36 |
$18,384 |
D/D |
1,059 |
44,929 |
2.74 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
EVP and COO |
• – – |
2013-12-31 |
4 |
B |
$33.92 |
$2,849 |
D/D |
84 |
45,013 |
2.66 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
EVP and COO |
• – – |
2014-06-30 |
4 |
B |
$43.79 |
$18,743 |
D/D |
428 |
53,885 |
2.74 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
EVP and COO |
• – – |
2014-10-10 |
4 |
B |
$44.91 |
$3,817 |
D/D |
85 |
53,970 |
2.66 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
EVP and COO |
• – – |
2014-12-31 |
4 |
B |
$45.23 |
$2,081 |
D/D |
46 |
55,016 |
2.66 |
- |
|
| VKTX |
Viking Therapeutics, Inc. |
Director |
– • – |
2015-05-04 |
4 |
B |
$8.00 |
$50,000 |
D/D |
6,250 |
6,250 |
2.39 |
- |
|
| QLGN |
Qualigen Therapeutics Inc |
Director |
– • – |
2015-06-24 |
4 |
B |
$5.00 |
$20,000 |
D/D |
4,000 |
4,000 |
2.39 |
- |
|
| QLGN |
Qualigen Therapeutics Inc |
Director |
– • – |
2016-01-08 |
4 |
B |
$1.64 |
$21,320 |
D/D |
13,000 |
17,000 |
2.39 |
- |
|
| VKTX |
Viking Therapeutics, Inc. |
Director |
– • – |
2016-04-13 |
4 |
B |
$1.24 |
$24,800 |
D/D |
20,000 |
26,250 |
2.39 |
- |
|
| VKTX |
Viking Therapeutics, Inc. |
Director |
– • – |
2016-11-15 |
4 |
B |
$1.21 |
$15,678 |
D/D |
13,000 |
39,250 |
2.39 |
- |
|
| QLGN |
Qualigen Therapeutics Inc |
Director |
– • – |
2017-05-18 |
4 |
B |
$0.62 |
$11,155 |
D/D |
18,000 |
35,000 |
2.39 |
- |
|
| QLGN |
Qualigen Therapeutics Inc |
Director |
– • – |
2018-08-17 |
4/A |
B |
$2.04 |
$40,292 |
D/D |
19,751 |
23,251 |
2.39 |
- |
|
| QLGN |
Qualigen Therapeutics Inc |
Director |
– • – |
2018-08-17 |
4 |
B |
$2.04 |
$40,292 |
D/D |
19,751 |
54,751 |
2.39 |
- |
|
| VKTX |
Viking Therapeutics, Inc. |
Director |
– • – |
2021-06-10 |
4 |
B |
$5.69 |
$113,800 |
D/D |
20,000 |
66,250 |
2.39 |
% |
|
| VKTX |
Viking Therapeutics, Inc. |
Director |
– • – |
2022-05-02 |
4 |
B |
$2.47 |
$111,195 |
D/D |
45,000 |
111,250 |
2.39 |
% |
|
136 Records found
|
|
Page 2 of 6 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
